Company & Sponsor Intelligence

University of Nebraska

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials10

Recruiting0

Completed7

Countries1

Therapeutic footprint

adhdalzheimersautismneuro_oncologyparkinsons

Indexed studies

NCT00792662Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
alzheimers · PHASE4

NCT03055533Headsprout Reading Program in Children With Autism Spectrum Disorder and Reading Delay
autism · United StatesNA

NCT02824627Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders
adhd · United StatesPHASE2

NCT06247176Sensory Habituation in Autism Spectrum Disorders
autism · United StatesNA

NCT01493219Biomarkers for Prognosis of Glioblastoma (GBM)
neuro_oncology · United StatesCOMPLETED

NCT00754208Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children
adhd · United StatesPHASE4

NCT03730194A SMART Design to Improve Sleep Disturbance in Adolescents With Neurodevelopmental Disorders
autism · United StatesNA

NCT04339543Longitudinal Analysis of Gait Variability to Predict Falls in Parkinson's Disease
parkinsons · United StatesNA

NCT00561340Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication
adhd · United StatesNA

NCT05677633Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease
parkinsons · United StatesPHASE1

Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →